Ranbaxy Mum On Lipitor Plans, Advises Patience Until Nov. 30 When "Reality" Will Emerge
This article was originally published in PharmAsia News
You may also be interested in...
MUMBAI - For Ranbaxy Laboratories Ltd., it has been nearly a decade-long bumpy ride to discover and develop its anti-malarial compound, but India's regulator - the Drug Controller General of India - finally granted the company a conditional approval to market the compound
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.